Serina Therapeutics, Inc. 8-K

What Happened Serina Therapeutics, Inc. (NASDAQ: SER) filed a Form 8‑K on July 22, 2026 announcing that Farrell Simon, Pharm.D., was appointed to the company’s Board of Directors effective July 22, 2026. Dr. Simon will also serve on the Audit Committee and the Compensation Committee. The company attached a press release announcing the appointment as Exhibit 99.1.

Key Details

• Appointment effective date: July 22, 2026.
• Committees: member of the Audit Committee and the Compensation Committee.
• Background: Dr. Simon is Chief Commercial Officer at Trevi Therapeutics and previously held senior commercial roles at Pfizer; holds a Pharm.D. and an MBA.
• Compensation: will be paid under Serina’s existing Director Compensation Policy.
• Independence/Related parties: Company reports no arrangements or understandings related to his selection and no material transactions requiring disclosure under Item 404(a) of Regulation S‑K.

Why It Matters This is a governance update that adds a director with commercial, lifecycle management, and business-development experience—skills relevant for a biotech company preparing for commercialization or partnerships. For investors, the appointment may strengthen Serina’s board expertise in commercial strategy and deal execution, but it does not change executive management or disclose any new financial metrics. The filing is informational and indicates no related‑party concerns or special compensation beyond the company’s standard director policy.